Skip to Content

Brovana Approval History

  • FDA approved: Yes (First approved October 6th, 2006)
  • Brand name: Brovana
  • Generic name: arformoterol tartrate
  • Dosage form: Inhalation Solution
  • Company: Sepracor Inc.
  • Treatment for: COPD

Brovana (arformoterol tartrate) is a long-acting beta2-agonist for inhalation via a nebulizer, used for the maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.

Development History and FDA Approval Process for Brovana

Oct  6, 2006Approval Brovana Sepracor Inc. - Treatment for Chronic Obstructive Pulmonary Disease
Feb 13, 2006Sepracor's Arformoterol NDA Filed by FDA; Drug Candidate for Chronic Obstructive Pulmonary Disease Moves Into Formal Review
Dec 13, 2005Sepracor Announces Submission of Arformoterol NDA to FDA for Chronic Obstructive Pulmonary Disease

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.